Astrocyte targeted SMN1 gene therapy and forskolin application improves astrocyte filopodia actin defects and motor neuron synaptic dysfunction in human SMA disease pathology

This study demonstrates that human spinal muscular atrophy (SMA) astrocytes exhibit intrinsic filopodia actin defects driven by reduced pERM levels, which contribute to motor neuron synaptic dysfunction, but these pathologies can be significantly ameliorated through a combined therapeutic strategy of astrocyte-targeted SMN1 gene therapy and forskolin treatment that restores pre-synaptic protein levels and improves synapse formation and function.

The Gist

The Big Picture: A Broken Bridge and a Wobbly Construction Crew

Imagine your nervous system is a massive, bustling city. The motor neurons are the delivery trucks that carry important packages (signals) to your muscles so you can move. The astrocytes are the construction crews and road maintenance teams that build the bridges (synapses) the trucks drive over and keep the roads smooth.

In a disease called Spinal Muscular Atrophy (SMA), the delivery trucks start to break down. But this study discovered something new: the construction crews (astrocytes) are also sick. They aren't just bystanders; they are actively failing to build the bridges properly, which makes the delivery trucks' jobs even harder.

The Problem: The "Filopodia" Fingers

Astrocytes have tiny, finger-like projections called filopodia (or Peri-Synaptic Astrocyte Processes). Think of these as the construction crew's fingers.

• Healthy Crew: Their fingers are long, flexible, and constantly reaching out to grab the delivery trucks, hold them steady, and ensure the packages get delivered.
• SMA Crew: Their fingers are short, stiff, and weak. They can't reach out effectively. Because their "fingers" are broken, the bridges (synapses) between the astrocytes and the motor neurons are weak or missing entirely.

Why are the fingers broken?
The study found that the SMA astrocytes are missing a specific "glue" and "motor" system.

1. Missing Glue (CD44): This is like the Velcro that helps the astrocyte stick to the road.
2. Broken Motor (pERM proteins): These are the tiny engines that power the movement of the fingers.
   Without these, the astrocyte fingers can't wiggle, grow, or hold onto the motor neurons.

The Experiment: Trying to Fix the Crew

The researchers wanted to see if they could fix the construction crew. They tried two different tools:

1. Tool A: SMN1 Gene Therapy (The "Fix-It Manual")
   SMA is caused by a missing instruction manual (the SMN1 gene). This therapy tries to give the astrocytes a copy of that manual.

   • Result: It helped a little bit. The crew got a bit stronger, but they still looked a bit clumsy and their fingers weren't fully flexible.

2. Tool B: Forskolin (The "Energy Drink")
   Forskolin is a chemical that wakes up the cells and tells them to move their cytoskeleton (their internal skeleton). Think of it as giving the construction crew a massive energy drink that makes them want to dance and stretch.

   • Result: This made the astrocyte fingers grow longer and more numerous, even without fixing the gene.

3. The Winning Combo: Manual + Energy Drink
   When the researchers gave the SMA astrocytes both the gene therapy (the manual) and the forskolin (the energy drink), the results were amazing.

   • The astrocytes grew beautiful, long, branching fingers.
   • They grabbed onto the motor neurons much better.
   • The "bridges" (synapses) became strong and functional again.

The Motor Neuron Rescue

When the construction crew (astrocytes) was fixed, the delivery trucks (motor neurons) got a huge boost:

• Before: The trucks were hyperactive, shaking and jittering (hyperexcitability) because the roads were bumpy and unstable. They were trying to deliver packages but kept crashing.
• After: With the new, strong bridges, the trucks calmed down. They stopped jittering and started delivering packages smoothly and efficiently.

The "Gender" Surprise

The study also noticed something interesting: The motor neurons from male patients seemed to suffer more damage than those from female patients. It's like the male trucks were carrying heavier loads and broke down faster when the roads were bad. The combination therapy worked particularly well to save these male trucks.

The Conclusion: A Two-Pronged Attack

The main takeaway is that fixing SMA isn't just about fixing the motor neurons (the trucks). You also have to fix the astrocytes (the construction crew).

• Old Idea: Just give the gene therapy to fix the missing manual.
• New Discovery: The manual helps, but it's not enough on its own because the astrocytes have their own "muscle memory" problems. You need to combine the gene therapy with a drug (forskolin) that wakes up the cell's movement systems.

In short: To fix the delivery trucks, you have to fix the road crew first. And to fix the road crew, you need to give them both the right instructions and a boost of energy to get them moving again. This "double therapy" approach could lead to better treatments for people with SMA.

Technical Summary

1. Problem Statement

Spinal Muscular Atrophy (SMA) is a neurodegenerative disease caused by the loss of the SMN1 gene, leading to reduced Survival of Motor Neuron (SMN) protein levels. While traditionally viewed as a motor neuron disease, recent evidence suggests non-cell autonomous mechanisms involving astrocytes contribute significantly to disease progression.

• The Gap: The specific mechanisms underlying tripartite synapse dysfunction (the interaction between motor neurons, sensory inputs, and peri-synaptic astrocyte processes or PAPs) in human SMA remain unclear.
• The Limitation: Previous studies showed that restoring SMN levels in astrocytes alone only partially rescues disease phenotypes (e.g., glutamate transporter EAAT1 levels) and fails to fully restore motor neuron function.
• The Hypothesis: SMA astrocytes possess intrinsic defects in actin cytoskeleton dynamics within their filopodia (PAPs), which disrupts synaptic stability and motor neuron function. A combination therapy targeting both SMN restoration and actin signaling pathways may be required for full therapeutic efficacy.

2. Methodology

The study utilized human induced pluripotent stem cell (iPSC)-derived models to investigate SMA pathology and test therapeutic interventions.

• Cell Models:
  • Monocultures: Astrocytes derived from healthy controls and SMA patients (Types 1 and 2).
  • Co-cultures: Motor neurons and astrocytes co-cultured to model the tripartite synapse.
  • Therapeutic Interventions:
    • SMN1 Gene Therapy: Lentiviral transduction to re-express SMN1 (FLAG-tagged or GFP-tagged) specifically in SMA astrocytes.
    • Forskolin Treatment: Application of forskolin (10 µM), an adenylyl cyclase activator that increases cAMP levels to stimulate actin remodeling via the CDC42 pathway.
• Analytical Techniques:
  • Proteomics: Microscale cell surface capture mass spectrometry to identify differentially abundant N-glycoproteins on the astrocyte surface.
  • Microscopy: Confocal microscopy, Structured Illumination Microscopy (SIM) for super-resolution imaging of filopodia, and Imaris software for 3D quantification of filopodia density and synapse colocalization.
  • Biochemistry: Cell fractionation (plasma membrane and synaptogliosome isolation) followed by Western blotting to quantify synaptic proteins (SYN1, PSD95) and PAP proteins (pERM, CD44, EAAT1).
  • Functional Assays:
    • Electrophysiology: Whole-cell patch-clamp recordings (voltage/current clamp) to measure input resistance, resting membrane potential, and action potential firing.
    • Multi-Electrode Arrays (MEA): To assess network-level bursting activity and synaptic connectivity.
  • Actin Remodeling Assay: ATP depletion (NaN3) followed by recovery to test dynamic filopodia responses.

3. Key Contributions

• Discovery of Intrinsic Astrocyte Defects: Identified that SMA astrocytes have intrinsic defects in actin dynamics within filopodia, characterized by reduced levels of the actin-linker protein phosphorylated ERM (pERM) and the hyaluronic acid receptor CD44.
• Sex-Specific Phenotype: Noted that synaptic defects, specifically the loss of the pre-synaptic protein Synapsin I (SYN1), were more severe in male-derived SMA cultures compared to female-derived cultures.
• Dual-Therapy Paradigm: Demonstrated that while SMN restoration alone is insufficient, combining astrocyte-targeted SMN1 gene therapy with forskolin (cAMP elevation) synergistically restores astrocyte morphology and motor neuron function.
• Synaptogliosome Profiling: Successfully isolated and characterized the "synaptogliosome" (the synaptic junction including the PAP), revealing specific molecular deficits in SMA that are distinct from whole-cell lysates.

4. Key Results

A. Astrocyte Surface Proteomics and Actin Defects

• Proteomics: SMA astrocytes showed a significant reduction in surface N-glycoproteins associated with actin dynamics (CD44, TENM2, TENM4) and an increase in inflammatory markers.
• Filopodia Dynamics: SMA astrocytes exhibited significantly lower filopodia density and failed to increase filopodia density upon actin remodeling stimulation (NaN3 recovery), unlike healthy astrocytes.
• Molecular Mechanism: This defect correlated with reduced levels of CDC42-GTP (active form), CD44, and pERM within filopodia. The CD44-pERM complex is crucial for tethering actin to the plasma membrane.

B. Synaptic Defects in Co-cultures

• Synaptogliosome Analysis: In SMA co-cultures, there was a significant reduction in the pre-synaptic protein SYN1 (Synapsin I), particularly in male-derived samples. PAP-associated proteins like pERM and EAAT1 were also reduced.
• Synapse Loss: Quantitative imaging revealed a significant decrease in the number of functional synapses (colocalization of SYN1/2 and PSD95) and predicted PAP regions in SMA co-cultures.

C. Therapeutic Efficacy (Dual Treatment)

• Forskolin Alone: Improved filopodia density in SMA astrocytes and increased SYN1 levels in motor neurons, but did not fully restore cell morphology or rheobase (minimum current to fire an action potential).
• SMN Alone: Partially restored filopodia density but failed to fully rescue synaptic protein levels or network bursting.
• Combined Therapy (SMN + Forskolin):
  • Morphology: Induced full stellation (branching) of SMA astrocytes, mimicking healthy morphology.
  • Protein Levels: Restored SYN1 levels in the synaptogliosome to healthy control levels.
  • Electrophysiology:
    • Normalized Input Resistance (Rin) (which was elevated in SMA).
    • Reduced hyperexcitability (action potential firing frequency).
    • Rescued Rheobase (only the dual treatment normalized this).
    • Restored network bursting activity in MEA recordings, which was absent in untreated SMA cultures.

5. Significance

• Mechanistic Insight: The study establishes that SMA pathology involves a non-cell autonomous mechanism where astrocyte actin defects (driven by low pERM/CD44) directly impair motor neuron synapse formation and function.
• Therapeutic Strategy: It challenges the notion that SMN restoration alone is sufficient. The data supports a combination therapy approach that targets both the root cause (SMN deficiency) and downstream effectors (actin signaling via cAMP/CDC42) to achieve robust functional recovery.
• Clinical Relevance: The findings suggest that patients receiving current SMN-based therapies (e.g., Zolgensma, Nusinersen) may still suffer from residual glial pathology. Adjunctive therapies targeting actin dynamics or cAMP pathways could improve clinical outcomes, particularly in preserving synaptic integrity.
• Sex Differences: The observation of more severe synaptic defects in male-derived lines highlights the need to consider sex-specific modifiers (potentially X-linked genes like PLS3) in SMA research and treatment stratification.

In conclusion, this paper defines a novel molecular pathway linking astrocyte actin cytoskeleton defects to motor neuron synaptic failure in SMA and proposes a dual-targeted therapeutic strategy that significantly outperforms monotherapies in restoring human disease phenotypes in vitro.